Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High throughput assessment of viability in 2D and 3D cell culture.

Methods in cell biology·2026
Same author

Mutational dynamics in patients with del(5q) MDS treated with lenalidomide prior to transfusion dependency-Molecular results from the Sintrarev clinical trial.

HemaSphere·2026
Same author

Protein tyrosine kinases in dendritic cell-mediated anti-cancer immunity.

Seminars in immunology·2026
Same author

Trial watch: antibody-drug conjugates in cancer therapy.

Oncoimmunology·2026
Same author

The autophagy-inhibitory tissue hormone DBI/ACBP is essential for glucocorticoid-induced immunosuppression.

Autophagy·2026
Same author

Restoring dendritic cell migration: a gut reaction to boost vaccine efficacy in aging.

Oncoimmunology·2026

Related Experiment Video

Updated: Apr 1, 2026

Viability Assays for Cells in Culture
12:03

Viability Assays for Cells in Culture

Published on: January 20, 2014

47.6K

High-throughput cell viability assessment using a luminescent ATP detection assay.

Dana Alawieh1, Marion Leduc2, Sebastien Nakhla1

  • 1INSERM U1287, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Methods in Cell Biology
|March 30, 2026
PubMed
Summary

Researchers screened existing drugs to find new treatments for chronic myelomonocytic leukemia (CMML). This high-throughput chemical drug screen identified potential genotype-dependent vulnerabilities, offering hope for targeted CMML therapies.

Keywords:
ATP detection luminescent assayDrug repurposingHigh-throughput drug screeningRobotized platformSuspension cell lines

More Related Videos

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

10.3K
Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines
12:35

Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines

Published on: September 3, 2016

20.3K

Related Experiment Videos

Last Updated: Apr 1, 2026

Viability Assays for Cells in Culture
12:03

Viability Assays for Cells in Culture

Published on: January 20, 2014

47.6K
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

10.3K
Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines
12:35

Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines

Published on: September 3, 2016

20.3K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic malignancy.
  • Current standard therapies lack the ability to eradicate leukemic clones or modify disease outcomes.
  • There are no approved targeted therapies for CMML, highlighting a significant therapeutic gap.

Purpose of the Study:

  • To identify genotype-dependent therapeutic vulnerabilities in CMML.
  • To leverage a drug repurposing strategy for rapid clinical translation of pre-approved compounds.
  • To address the unmet therapeutic needs in CMML treatment.

Main Methods:

  • Conducted a high-throughput chemical drug screen using a robotized platform.
  • Utilized four genetically engineered hematopoietic murine cell lines modeling recurrent CMML mutations.
  • Assessed cell viability using the CellTiter-Glo® luminescent cell viability assay over 48 hours.

Main Results:

  • Identified potential drug candidates through a genotype-dependent screening approach.
  • Demonstrated the feasibility of a drug repurposing strategy for CMML.
  • The CellTiter-Glo® assay proved accurate and efficient for high-throughput screening.

Conclusions:

  • High-throughput drug screening can identify novel therapeutic vulnerabilities in CMML.
  • Drug repurposing offers a promising avenue for developing targeted CMML therapies.
  • The described screening method is reliable, time-efficient, and adaptable for various research contexts.